Forney-Robinson-Pascoe Syndrome

Forney-Robinson-Pascoe syndrome is a very rare genetic condition. It mainly affects the heart, the bones and joints (especially in the neck, hands, and feet), hearing, growth, and facial features. Doctors today usually call it Cardiospondylocarpofacial (CSCF) syndrome. In most people, the cause is a change (pathogenic variant) in a single gene called MAP3K7. This gene helps cells respond to signals that guide normal development of the heart, bones, and inner ear. When the gene does not work correctly, the heart valves and septa, the small bones of the wrist and ankle, the bones in the neck, and the structures of the ear may not form normally. The condition is typically autosomal dominant, which means one changed copy of the gene can cause it; many cases arise de novo (new in the child). Orpha.net+3NCBI+3MalaCards+3

It’s an older synonym for Cardiospondylocarpofacial syndrome (CSCF; OMIM #157800)—an ultra-rare, autosomal-dominant genetic condition caused by heterozygous variants in MAP3K7 (which encodes TAK1, a key kinase in TGF-β/BMP signaling). Core features combine congenital heart disease (often mitral valve dysplasia/regurgitation), conductive hearing loss, short stature, brachydactyly with carpal/tarsal fusion, and cervical vertebral synostosis, with typical facial dysmorphism. Only a few dozen cases have been described. Wikipedia+2NCBI+2

Changes (mutations) in one copy of the MAP3K7 gene disrupt TAK1, a signaling “switch” cells use when reading TGF-β/BMP growth messages. During early development, these messages guide how the heart valves, bones of the spine/hands/feet, and the middle/inner ear form. When TAK1 misfires, the result can be valve dysplasia/regurgitation, fusions of small wrist/ankle bones, neck vertebrae joining together, and malformed middle/inner ear structures that cause conductive hearing loss. PubMed+2PMC+2

Typical features include mitral valve disease (often regurgitation), hearing loss (often conductive), short stature, and fusion of some bones in the wrist/ankle and the cervical (neck) spine. Facial traits may include wide-spaced eyes, up-slanting eyelids, a long philtrum, and rotated ears. Genetic Rare Diseases Center+1

The syndrome was first described in 1966 by Forney, Robinson, and Pascoe in a family with congenital heart disease, deafness, and skeletal malformations. Later research discovered MAP3K7 as the main gene. Wiley Online Library+1

Other names

Doctors and databases may use any of these names for the same condition:

• Cardiospondylocarpofacial syndrome (CSCF). NCBI

• Forney-Robinson-Pascoe syndrome (historic name). MeSH Browser+1

• Forney syndrome. Global Genes

• Mitral regurgitation–deafness–skeletal anomalies syndrome (describes the main triad). Global Genes

• Congenital heart disease, deafness, and skeletal malformations (descriptive label used in early reports and MeSH). MeSH Browser

Types

There is no official “type 1, type 2…” system. Instead, clinicians think of one condition with a spectrum. A helpful way to group it is by which body systems are most affected in a given person:

1. Cardiac-predominant CSCF. Main issues are mitral valve regurgitation, valve dysplasia, or septal defects; other features are mild. MalaCards

2. Skeletal-predominant CSCF. Neck (cervical) vertebrae fusion and carpal/tarsal coalitions are prominent; stature is short; joint laxity may be present. MalaCards

3. Oto-skeletal CSCF. Conductive hearing loss with inner ear malformations plus bone fusions are the main findings; heart disease is milder. MalaCards

4. Classic multi-system CSCF. Heart, skeleton, hearing, growth, and facial traits are all present, matching the historic triad. Genetic Rare Diseases Center

These groupings simply reflect phenotypic variability seen across reports; they are not separate diseases. NCBI

Causes

1. Pathogenic variants in MAP3K7. The central cause in most patients; MAP3K7 encodes TAK1, a kinase in TGF-β/related pathways essential for heart, bone, and ear development. NCBI

2. Autosomal dominant inheritance. One altered copy of MAP3K7 is sufficient to cause disease. MalaCards

3. De novo variants. Many cases arise new in the affected child with unaffected parents. NCBI

4. Missense variants in MAP3K7. Single-letter amino-acid changes can alter TAK1 function and downstream signaling. (Mechanism summarized in the OMIM/MedGen overview.) NCBI

5. Loss-of-function variants (nonsense/frameshift). Truncating changes can reduce or abolish TAK1 protein, disturbing development. (Inferred from gene-disease mechanism described for CSCF.) NCBI

6. Splice-site variants. Changes at intron/exon boundaries can mis-splice MAP3K7 RNA, lowering normal protein. NCBI

7. Impaired TGF-β–activated kinase signaling. The shared pathway effect explains multi-system findings (heart valves, cartilage/bone, ear). NCBI

8. Abnormal NF-κB pathway modulation. TAK1 also interacts with NF-κB routes important in morphogenesis; disruption contributes to features. (Mechanistic context from MAP3K7 function summaries linked to CSCF.) MalaCards

9. Inner ear development disruption. MAP3K7 dysfunction can lead to conductive or mixed hearing loss via malformations. MalaCards

10. Cardiac valve morphogenesis defects. The gene’s pathway helps sculpt valves; defects lead to mitral regurgitation or dysplasia. MalaCards

11. Abnormal vertebral segmentation. Disturbed signaling during somitogenesis may cause cervical vertebral fusion. MalaCards

12. Carpal/tarsal coalition. Mal-patterning of wrist/ankle bones yields bony fusions typical of CSCF. MalaCards

13. Post-zygotic mosaicism (rare). If a variant occurs after fertilization, only some tissues carry it, producing variable severity. (General genetic principle applied to AD disorders.) NCBI

14. Genetic heterogeneity (rare/possible). Most evidence points to MAP3K7, but reports prior to gene discovery used descriptive names; other loci have not been firmly established. Wiley Online Library

15. Founder effects in families. Shared variants within a family line can cause multiple affected relatives across generations. (Autosomal dominant pattern noted in summaries.) MalaCards

16. Variable expressivity. The same variant may cause milder or more severe findings in different people. (Documented phenotypic spectrum.) NCBI

17. Age-related penetrance of some features. Certain skeletal fusions or valve changes may become more evident with growth. (Clinical course implied by skeletal/valvular findings.) MalaCards

18. Environmental modifiers (secondary). Nutrition, infections, or other health factors do not cause CSCF but can influence growth or hearing outcomes. (General principle; primary cause remains genetic.) Genetic Rare Diseases Center

19. Diagnostic delay/mislabeling. Historic labels (e.g., “Forney syndrome”) may obscure MAP3K7 etiology until genetic testing is done. Global Genes+1

20. Literature lineage from the original family. The 1966 family described by Forney, Robinson, and Pascoe set the triad; modern genetics later unified cases under CSCF with MAP3K7. Wiley Online Library

Symptoms and signs

1. Mitral valve regurgitation. The mitral valve can be leaky because its leaflets or supporting structures formed abnormally, causing blood to flow backward from the left ventricle to the left atrium. Severity ranges from mild to significant and may change over time. Global Genes+1

2. Other heart defects. Some people have septal defects (holes in the heart walls) or valve dysplasia in addition to mitral disease. These can affect oxygen levels, growth, and exercise tolerance. MalaCards

3. Conductive hearing loss. Sound waves are not transmitted efficiently through the outer/middle ear because of structural changes; many patients need hearing support early in life. Genetic Rare Diseases Center

4. Inner ear malformations. Imaging may show differences in the middle/inner ear bones or canals that explain the hearing pattern. MalaCards

5. Short stature / growth delay. Many children grow more slowly and are shorter than peers, sometimes linked with feeding difficulties in infancy. Genetic Rare Diseases Center

6. Carpal and tarsal bone fusion. Some small wrist and ankle bones are joined, which can limit range of motion or cause discomfort during certain activities. MalaCards

7. Cervical vertebral fusion. Neck bones can be partially fused, sometimes leading to reduced neck mobility or, rarely, nerve symptoms if severe. MeSH Browser+1

8. Brachydactyly (short fingers/toes). Digits can be shorter or differently shaped; this is often mild but noticeable on exam or X-ray. MalaCards

9. Joint laxity. Some children have looser joints, which may improve with age and strengthening exercises. MalaCards

10. Facial features. Wide-spaced eyes, up-slanting eyelids, a long philtrum, and rotated ears are reported; these traits help doctors recognize the pattern. MalaCards

11. Feeding difficulty / failure to thrive in infancy. Early feeding and weight gain can be challenging, especially if there is significant heart disease. Genetic Rare Diseases Center

12. Reflux or gastrointestinal symptoms. Some children have reflux that can worsen feeding issues and growth. MalaCards

13. Short extremities. Arms or legs may be relatively short compared with the trunk length. MalaCards

14. Genitourinary anomalies (occasional). Some reports include kidney or urinary tract differences, which are typically mild but merit screening. MalaCards

15. Bilateral conductive hearing loss with middle ear changes. The hearing pattern is often bilateral and conductive, aligning with structural findings on imaging. MalaCards

Diagnostic tests

A) Physical examination

1. General pediatric/clinical exam. The clinician documents growth (height, weight, head size), facial features, and overall development. Findings like short stature, facial pattern, and short digits raise suspicion. Genetic Rare Diseases Center

2. Cardiac auscultation. A systolic murmur at the apex can suggest mitral regurgitation; abnormal heart sounds prompt echocardiography. Global Genes

3. Musculoskeletal exam of neck and limbs. Limited neck rotation or wrist/ankle stiffness points toward vertebral and carpal/tarsal fusions. MalaCards

4. Ear, nose, and throat (ENT) exam. Otoscopic exam may show middle-ear issues that fit a conductive hearing pattern and guide referral for hearing testing. Genetic Rare Diseases Center

B) Manual/bedside tests

5. Bedside hearing checks and tuning fork tests. Simple Rinne/Weber tests can quickly screen for conductive versus sensorineural loss before formal audiology. Genetic Rare Diseases Center

6. Range-of-motion assessment. Gentle manual testing of the neck and wrists/ankles helps document motion limits due to bone fusion. MalaCards

7. Functional hand/foot assessment. Grip, pinch, gait, and balance testing identify activity limits related to carpal/tarsal coalitions. MalaCards

8. Growth charting and nutritional screening. Serial plotting can show persistent short stature or failure to thrive, prompting nutrition support. Genetic Rare Diseases Center

C) Laboratory and pathological tests

9. Genetic testing for MAP3K7. Next-generation sequencing panels or whole-exome/genome testing can directly detect the causal variant and confirm the diagnosis. NCBI

10. Variant confirmation and segregation studies. Sanger confirmation and testing of parents clarify whether a variant is inherited or de novo, informing recurrence risk. NCBI

11. Copy-number analysis (as indicated). While most cases are sequence variants, labs may also evaluate for rare deletions/duplications involving MAP3K7. NCBI

12. Basic metabolic panels (supportive). Routine labs are not diagnostic for CSCF but assess overall health before anesthesia or surgery for heart or ear procedures. (Supportive practice; primary diagnosis is clinical + genetic.) Genetic Rare Diseases Center

13. Thyroid and nutrition labs (selective). In children with poor growth or feeding issues, clinicians may run screening labs to exclude other contributors to growth delay. (Supportive practice alongside genetic diagnosis.) Genetic Rare Diseases Center

14. Pathology of resected tissue (rare). If orthopedic or cardiac surgery is done, tissue examination is standard for surgical quality assurance, not for primary diagnosis. (General clinical practice principle.) MalaCards

D) Electrodiagnostic tests

15. Electrocardiogram (ECG). Records heart rhythm and chamber strain that might accompany structural defects; often normal but useful pre-op. MalaCards

16. Brainstem auditory evoked potentials (BAEP/ABR). Objective test of hearing pathway function, helpful in infants and young children. Genetic Rare Diseases Center

17. Impedance tympanometry. Measures eardrum and middle-ear mechanics to support the diagnosis of conductive hearing loss. Genetic Rare Diseases Center

E) Imaging tests

18. Transthoracic echocardiography. The key test for valve structure and function, quantifying mitral regurgitation and looking for septal defects. Global Genes

19. Cardiac MRI (select cases). Provides detailed valve and ventricular assessment when echo images are limited or surgical planning is needed. (Standard cardiac imaging practice for congenital valve disease.) MalaCards

20. X-rays of the cervical spine and wrists/ankles. Show vertebral fusion and carpal/tarsal coalitions that are characteristic. MalaCards

21. CT or MRI of the cervical spine. Offers clearer 3D detail of vertebral synostosis for surgical or safety planning (e.g., anesthesia, sports). MalaCards

22. Temporal bone CT (ear). Maps middle/inner ear anatomy to guide hearing management (e.g., surgery, devices). MalaCards

23. Hand/foot MRI (select cases). Helps in pre-operative planning or when X-rays are inconclusive about small bone coalitions. MalaCards

Non-pharmacological treatments

(Because CSCF is ultra-rare, guidance is extrapolated from core problems—valvular disease, skeletal fusions, and conductive hearing loss.)

1. Congenital heart disease clinic follow-up – Regular cardiology visits catch valve leakage or heart enlargement early; this prevents silent decline by adjusting timing for surgery or medical therapy. Mechanism: surveillance + timely intervention reduces volume overload from mitral regurgitation. Orpha.net

2. Echocardiography surveillance plan – Scheduled echos (e.g., annually or per cardiology advice) quantify regurgitant volume and LV size/function so action occurs before permanent damage. Mechanism: image-guided risk control. NCBI

3. Valve-repair/heart-team conference – Early discussion among cardiology, cardiac surgery, and anesthesia tailors the safest, least invasive plan (repair preferred over replacement when feasible in children). Mechanism: team decisions improve outcomes in congenital valve disease. Orpha.net

4. Hearing aids (air-conduction) and assistive listening – Amplification overcomes conductive loss so speech and learning can progress on time. Mechanism: boosts sound energy to bypass partial middle-ear inefficiency. Orpha.net

5. Bone-anchored hearing systems (BAHS) – When conductive loss is large or anatomy is atypical, BAHS vibrates skull bone to send sound straight to the inner ear. Mechanism: bone conduction bypasses middle-ear blockage. Orpha.net

6. Speech-language therapy – Supports articulation and language acquisition when early hearing loss delayed input. Mechanism: intensive practice strengthens alternative language pathways. Orpha.net

7. Early-intervention/education services – Classroom accommodations (FM systems, seating, captioning) protect learning despite hearing limits. Mechanism: raises signal-to-noise in real settings. Orpha.net

8. Physical therapy (PT) – Maintains neck/shoulder mobility around cervical fusions and improves posture and balance; individualized to avoid stressing fused segments. Mechanism: targeted strengthening and flexibility. Orpha.net

9. Occupational therapy (OT) – Hand function training helps with carpal fusion (grip, fine motor, tool adaptation). Mechanism: task-oriented practice improves daily living skills. Orpha.net

10. Orthotic supports/splints – Neutral wrist/hand splints reduce pain and improve leverage when bones are fused. Mechanism: external alignment redistributes load. Orpha.net

11. Activity modification & ergonomic schooling – Avoid extreme neck flexion/extension due to cervical synostosis; teach safe biomechanics. Mechanism: reduces risk of nerve/cord irritation. Orpha.net

12. Pain self-management training – Heat/ice, pacing, relaxation for musculoskeletal discomfort from altered joint mechanics. Mechanism: non-drug analgesia pathways. Orpha.net

13. Nutrition & growth monitoring – Many children have feeding difficulty and FTT; involve dietetics and feeding therapy as needed. Mechanism: adequate calories and micronutrients support growth and healing. Orpha.net

14. Dental/airway assessment – High palate and dysmorphism can affect dentition and airway; periodic dental/airway checks prevent secondary issues. Mechanism: early detection of malocclusion/OSA risk. Orpha.net

15. Genetic counseling – Explains autosomal-dominant inheritance, testing options for relatives, and reproductive choices. Mechanism: informed family planning and cascade testing. NCBI

16. Psychosocial support – Coping skills and family support for rare-disease stress; connects to patient organizations. Mechanism: reduces caregiver burden, improves adherence. Global Genes

17. Fall-prevention and home safety – Balance training when cervical fusions alter range; home adaptations reduce injury risk. Mechanism: environmental risk reduction. Orpha.net

18. Cardiac rehabilitation (age-appropriate) – Safe aerobic conditioning when cardiology allows; improves exercise tolerance. Mechanism: graded training strengthens heart and muscles. Orpha.net

19. Vaccination up-to-date – Protects against otitis media complications and endocarditis-related bacteremia risk by lowering infection burden. Mechanism: fewer infections → fewer cardiac/ENT setbacks. Orpha.net

20. Care coordinator/navigator – One point person aligns cardiology, ENT, ortho, rehab, and school supports. Mechanism: fewer delays and missed care steps. Orpha.net

---

Drug treatments

Important: There is no FDA-approved drug for CSCF itself. Medicines below are commonly used for valve regurgitation consequences, peri-operative care, ear disease, or pain. Always dose by clinician judgment and pediatric standards when relevant.

1. Furosemide (loop diuretic) – Relieves fluid overload if significant MR leads to congestion; typical oral starting range per label; monitor electrolytes/renal function. Mechanism: blocks NKCC2 in loop of Henle → diuresis. Cleveland Clinic

2. Enalapril / Lisinopril (ACE inhibitors) – Afterload reduction may ease regurgitant volume and LV remodeling in MR; label dosing titrated to BP/renal function. Mechanism: ↓ angiotensin II → vasodilation/afterload drop. Cleveland Clinic

3. Losartan (ARB) – Alternative to ACEi for afterload reduction/intolerance (cough/angioedema with ACEi). Mechanism: AT1 blockade. Cleveland Clinic

4. Metoprolol (β-blocker) – Rate control and anti-ischemic benefits when indicated; may help symptomatic palpitations. Mechanism: β1 blockade reduces HR and myocardial oxygen demand. Cleveland Clinic

5. Spironolactone – For persistent fluid overload with ACEi/diuretic; monitor K+/renal function. Mechanism: aldosterone antagonism limits remodeling. Cleveland Clinic

6. Torsemide/Bumetanide – Alternative loops for diuretic resistance; label-guided dosing. Mechanism: potent natriuresis. Cleveland Clinic

7. Acetaminophen – First-line analgesic for musculoskeletal discomfort (avoid NSAIDs if renal concerns from diuretics/ACEi). Mechanism: central COX modulation (analgesia/antipyresis). Cleveland Clinic

8. Amoxicillin (peri-procedural prophylaxis in select cases) – Only if current AHA criteria for infective endocarditis prophylaxis are met (not all valve disease qualifies). Mechanism: short-course bactericidal cover against oral streptococci during invasive dental work. (Follow guidelines; not routine for every MR.) Cleveland Clinic

9. Topical nasal steroids – Reduce Eustachian tube inflammation and help otitis media with effusion in selected patients. Mechanism: local anti-inflammatory effect. Orpha.net

10. Ofloxacin ear drops – For otorrhea with tympanostomy tubes or chronic suppurative otitis media. Mechanism: local quinolone antibacterial. Orpha.net

11. Vitamin D (medication-grade where deficient) – Corrects deficiency to support bone health around fusions; lab-guided dosing. Mechanism: improves calcium handling/bone turnover. Orpha.net

12. Iron therapy (if iron-deficiency anemia) – Optimizes oxygen delivery pre-op or in chronic disease. Mechanism: hemoglobin synthesis. Orpha.net

13. Ondansetron (peri-op nausea control) – Better tolerance of anesthesia and recovery after ENT/orthopedic/cardiac procedures. Mechanism: 5-HT3 antagonism. Cleveland Clinic

14. Amoxicillin-clavulanate (acute bacterial otitis media) – Treats superimposed infections impacting hearing and speech progress. Mechanism: β-lactam + β-lactamase inhibitor. Orpha.net

15. Ciprofloxacin-dexamethasone otic – For persistent canal inflammation/otorrhea under ENT care. Mechanism: antibacterial + anti-inflammatory. Orpha.net

16. Gabapentin (selected neuropathic pain) – Rarely used, but may help chronic neck/shoulder neuropathic pain after surgery; specialist-directed. Mechanism: α2δ subunit modulation. Cleveland Clinic

17. Peri-operative anticoagulation/antiplatelet protocols (post-valve repair/replacement) – As directed by cardiac surgery/cardiology to prevent thromboembolism. Mechanism: reduces clot risk on prosthetic material. Orpha.net

18. Antibiotic peri-op prophylaxis (ENT/ortho/cardiac) – Procedure-specific regimens reduce surgical-site infection. Mechanism: transient bacteremia suppression. Orpha.net

19. Topical analgesics (e.g., lidocaine patches over muscular trigger zones) – Adjunct for musculoskeletal pain without systemic effects. Mechanism: local sodium-channel blockade. Orpha.net

20. Proton-pump inhibitor (short course if NSAIDs are unavoidable) – GI protection when NSAIDs are temporarily necessary and benefits outweigh risks. Mechanism: gastric acid suppression. Cleveland Clinic

Why FDA labeling is limited here: CSCF is not a labeled indication for any medication. Drug choices above follow general label guidance for the associated conditions or peri-operative care, not for CSCF itself. For precise labels/doses, clinicians consult the FDA label for each specific product.

---

Dietary molecular supplements

1. Vitamin D & Calcium (lab-guided) – Supports bone health in the context of congenital fusions and limited loading; deficiency is common globally. Mechanism: mineralization and remodeling support. Orpha.net

2. Iron (if low ferritin) – Optimizes pre-op reserve and reduces fatigue from anemia. Mechanism: hemoglobin synthesis. Orpha.net

3. Omega-3 fatty acids – May modestly support cardiometabolic health; safe adjunct when surgery is planned (stop pre-op per surgeon preference). Mechanism: triglyceride lowering, anti-inflammatory effects. Orpha.net

4. Folate/B-complex (deficiency correction) – Supports hematologic and neural function during growth/development. Mechanism: methylation/erythropoiesis. Orpha.net

5. Zinc (if deficient) – Wound healing and immune support peri-op. Mechanism: enzyme cofactor for repair. Orpha.net

6. Magnesium (if low) – Maintains rhythm and muscle function, especially with diuretic use. Mechanism: electrolyte balance. Cleveland Clinic

7. Protein-rich nutrition (dietary, not pills) – Supports growth and surgical healing; consider supplements if intake is poor. Mechanism: substrate for tissue repair. Orpha.net

8. Vitamin C (dietary focus) – Collagen synthesis and wound healing; avoid megadoses peri-op unless advised. Mechanism: cofactor for hydroxylation in collagen. Orpha.net

9. Iodine-adequate diet – General thyroid support for growth; ensure adequate but avoid excess. Mechanism: thyroid hormone synthesis. Orpha.net

10. Probiotics (select cases) – May reduce antibiotic-associated diarrhea during ENT/cardiac peri-op courses; product-specific evidence varies. Mechanism: microbiome modulation. Orpha.net

---

Immunity booster / regenerative / stem-cell drugs

There are no approved immune-booster or stem-cell drugs for CSCF. The condition is developmental from MAP3K7 variants; treatment is structural and supportive. Stem-cell therapies are not indicated for bone fusions or valve dysplasia in CSCF. Focus instead on vaccines, nutrition, infection prevention, and timely surgery/hearing rehabilitation. PubMed+1

---

Surgeries (what they do & why)

• Mitral valve repair/replacement – Corrects regurgitation or dysplasia to stop back-flow and protect the left ventricle. Timing depends on symptoms, LV size/function, and regurgitation severity. Orpha.net

• Tympanostomy tubes / middle-ear surgery – Ventilates the middle ear, reduces effusions/infections, and improves hearing thresholds when medical care is insufficient. Orpha.net

• Bone-anchored hearing implant surgery – Places a percutaneous or magnet-coupled abutment to transmit sound by bone. Orpha.net

• Hand/foot corrective procedures – Select osteotomies or releases for carpal/tarsal fusion if function/pain demand it; chosen cautiously because fusion patterns vary. Orpha.net

• Cervical spine procedures (rare) – Only for myelopathy/instability or severe deformity; most cases managed conservatively. Orpha.net

---

Preventions

1. Regular cardiology surveillance & timely surgery decisions. Orpha.net

2. ENT/audiology follow-up to prevent speech delay from hearing loss. Orpha.net

3. Vaccinations (childhood, influenza, pneumococcal as indicated). Orpha.net

4. Prompt treatment of ear and dental infections to reduce bacteremia load. Orpha.net

5. Neck-safe movement habits; avoid high-risk sports if cervical fusion limits range. Orpha.net

6. Nutrition optimization and growth tracking. Orpha.net

7. Peri-procedural antibiotic prophylaxis only when guideline criteria are met. Cleveland Clinic

8. Sun-sensible, bone-healthy lifestyle (vitamin D, weight-bearing as allowed). Orpha.net

9. School accommodations to prevent learning setbacks (FM systems, seating). Orpha.net

10. Care coordination to avoid missed referrals or late interventions. Orpha.net

---

When to see a doctor

• New or worsening shortness of breath, fatigue, palpitations, chest pain, or fainting—possible valve worsening. Orpha.net

• Ear pain, drainage, or sudden hearing changes, especially if using hearing devices. Orpha.net

• Neck pain, limb weakness, numbness, balance changes, or new gait trouble—evaluate cervical spine. Orpha.net

• Poor weight gain, feeding difficulties, or frequent respiratory infections in children. Orpha.net

• Before dental/ENT/orthopedic procedures—to plan anesthesia and prophylaxis appropriately. Cleveland Clinic

---

What to eat & what to avoid

Eat more of: balanced protein sources; iron-rich foods if anemic; calcium- and vitamin-D-containing foods; fruits/vegetables for wound healing and general health; adequate fluids if on diuretics (per cardiology). Avoid/limit: very high-salt diets (worsen fluid retention with MR); excessive caffeine/energy drinks (palpitations); NSAID overuse (kidney strain if on ACEi/diuretics); crash diets that impair growth or healing. Always tailor to your cardiologist/dietitian’s plan. Orpha.net+1

---

FAQs

1. Is CSCF the same as Forney-Robinson-Pascoe syndrome? Yes—different names for the same disorder. Wikipedia

2. What gene is involved? MAP3K7 (TAK1) with autosomal-dominant inheritance. PubMed

3. How common is it? Extremely rare—only a small number of families reported. Wikipedia

4. What causes the heart problems? Valve/structural maldevelopment from disrupted TGF-β/BMP signaling during embryonic growth. PubMed

5. Can medicines “fix” the gene? No. Medicines treat consequences (e.g., fluid overload) but not the gene change. PubMed

6. Will hearing always be affected? Conductive loss is common; devices or surgery often improve function. Orpha.net

7. Is surgery always needed for the valve? No. Timing depends on symptoms and echo findings. Orpha.net

8. Is intelligence affected? Most reports focus on structural issues; neurodevelopment varies and is not the defining feature. Orpha.net

9. Can the spine fusion be dangerous? It limits motion and can cause pain; neurological symptoms need urgent evaluation. Orpha.net

10. Will this pass to children? Each child has a 50% chance if a parent carries the variant. Genetic counseling is key. NCBI

11. How is it confirmed? Clinical pattern + MAP3K7 molecular testing. NCBI

12. Are there research updates? New case reports/variants continue to expand the phenotype (e.g., 2024). Nature

13. Is there a patient registry or info hub? Rare-disease portals (Orphanet, Global Genes, NORD/MONDO/MedGen) summarize evolving knowledge. Orpha.net+2Global Genes+2

14. Any overlap with other MAP3K7 disorders? Yes—frontometaphyseal dysplasia type 2 is also MAP3K7-related, with a different bone pattern. Wiley Online Library

15. What’s the long-term outlook? Depends on valve severity, hearing rehabilitation, and musculoskeletal symptoms; proactive, team-based care improves quality of life. Orpha.net

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 11, 2025.